Lung Cancer News

Neoadjuvant atezolizumab prior to chemoradiation therapy exhibited promising activity for patients with unresectable stage III non-small cell lung cancer, according to results of a nonrandomized phase 2 study.

Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been discontinued due to lack of efficacy, according to the agent’s manufacturer.

A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.

In 2018, at the height of the chimeric antigen receptor T-cell therapy revolution and in the heart of its implementation, Healio’s Cell Therapy Next staff went onsite to University of Pennsylvania’s newly minted center.

Alternative lung cancer screening criteria may identify more individuals, who would benefit from screening compared with current guidelines, study results showed.

Current evidence does not support lung cancer screening for never-smokers or former light smokers with a family history of lung cancer, according to a commentary in Journal of Thoracic Oncology.

Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.

Exposure of certain cardiac structures to radiation during treatment of surgically inoperable or unresectable non-small cell lung cancer was associated with increased arrhythmia risk, researchers reported.

A lung nodule sized 30 mm3 or greater was found in 42% of adults in Northern Europe who reported either never smoking or former smoking, according to results published in Radiology.

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.